SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 114.70K | 114.70K | 377.80K | 1.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 114.70K | 114.70K | 377.80K | 1.32M |
| Cost of Revenue | 33.35M | 29.75M | 29.74M | 43.54M | 44.03M |
| Gross Profit | -33.35M | -29.63M | -29.63M | -43.16M | -42.71M |
| SG&A Expenses | 15.60M | 12.73M | 12.50M | 13.41M | 14.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.95M | 43.31M | 41.94M | 42.67M | 44.23M |
| Operating Income | -48.95M | -43.19M | -41.82M | -42.29M | -42.91M |
| Income Before Tax | 13.27M | 18.74M | -37.06M | -34.28M | -34.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.27 | 18.74 | -37.06 | -34.28 | -34.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.27M | 18.74M | -37.06M | -34.28M | -34.11M |
| EBIT | -48.95M | -43.19M | -41.82M | -42.29M | -42.91M |
| EBITDA | -45.87M | -40.09M | -38.52M | -38.71M | -38.12M |
| EPS Basic | 0.63 | -0.54 | -2.15 | -3.70 | -3.68 |
| Normalized Basic EPS | 1.42 | 0.87 | -2.49 | -2.31 | -2.30 |
| EPS Diluted | -0.27 | -1.25 | -2.16 | -3.70 | -3.69 |
| Normalized Diluted EPS | -0.88 | -1.43 | -2.49 | -2.31 | -2.30 |
| Average Basic Shares Outstanding | 77.25M | 38.54M | 37.14M | 37.10M | 37.05M |
| Average Diluted Shares Outstanding | 144.45M | 105.75M | 37.14M | 37.10M | 37.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |